Business
Dato-DXd improved PFS in breast cancer
Dato-DXd improved PFS in breast cancer.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n\nThis announcement contains inside information\n \n22 September 2023\n \nDatopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive,\nHER2-low or negative breast cancer in TROPION-Breast01 Phase III trial\n \nFirst Phase III results in breast cancer for AstraZeneca\nand Daiichi Sankyo's datopotamab deruxtecan\n \nPlans for global regulatory submissions underway\n \nPositive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival (PFS) compared to investigator's choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer previously treated with endocrine-based therapy and at least one systemic therapy.\n \nA trend in improvement for the dual primary endpoint of overall survival (OS) was observed for datopotamab deruxtecan versus chemotherapy. Data for OS were not mature at this interim analysis and the trial will continue as planned to assess OS.\n \nThe safety profile of datopotamab deruxtecan was consistent with previous clinical trials in breast cancer with no new safety signals identified. All grade interstitial lung disease rates were low. \n \nDatopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.\n \nSusan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: \"Today's TROPION-Breast01 news is a significant development for patients with HR-positive, HER2-low or negative metastatic breast cancer whose tumours have become insensitive to endocrine therapy and who currently face poor outcomes. We are encouraged by these positive results.\"\n \nKen Takeshita, MD, Global Head, Oncology R&D, Daiichi Sankyo, said: \"The positive topline results from TROPION-Breast01 demonstrate the potential for datopotamab deruxtecan to become an important treatment option for patients with HR-positive, HER2-low or HER2-negative breast cancer in the second-line metastatic setting. We look forwar...